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What is the key question? 
Is augmented extracellular matrix (ECM) deposition by small airway smooth muscle 
cells in COPD underpinned by a unique epigenetic mechanism? 
What is the bottom line? 
Increased expression of ECM genes COL15A1 and TNC in COPD is modulated by 
histone H4 acetylation. 
Why read on? 
Further investigations demonstrate the link between BET proteins and the propagation 
of aforementioned histone H4 acetylation in COPD cells. 
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Rationale: In COPD, small airway fibrosis occurs due to increased extracellular matrix (ECM) 
deposition in and around the airway smooth muscle (ASM) layer. Studies of immune cells and 
peripheral lung tissue have shown that epigenetic changes occur in COPD but it is unknown 
whether airway mesenchymal cells are reprogrammed.  
Objectives: Determine if COPD ASM cells have a unique epigenetic response to pro-fibrotic 
cytokine TGF-β1. 
Methods: Primary human ASM cells from COPD and non-COPD smoking patients were 
stimulated with TGF-β1. Gene array analysis performed to identify differences in ECM 
expression. Airway accumulation of collagen 15α1 and tenascin-C proteins were assessed. 
COPD and non-COPD patients’ ASM cells were stimulated with TGF-β1 ±  epigenetic 
inhibitors with qPCR carried out for COL15A1 and TNC. Global HAT and HDAC activity were 
assessed. ChIP-qPCR for histone H3 and H4 acetylation at COL15A1 and TNC promoters was 
carried out. Effects of BET inhibitor JQ1(+) on expression and acetylation of ECM target genes 
was assessed. 
Measurements and Main Results: COPD ASM show significantly higher COL15A1 and TNC 
expression in vitro and significantly higher levels of collagen 15α1 deposited in COPD airways 
in vivo. Epigenetic screening indicated differential response to HDAC inhibition. ChIP-qPCR 
revealed histone H4 acetylation at COL15A1 and TNC promoters in COPD ASM only. ChIP-
qPCR found JQ1(+) pre-treatment significantly abrogated TGF-β1 induced histone H4 
acetylation at COL15A1 and TNC. 
Conclusions: BET protein binding to acetylated histones is important in TGF-β1 induced 
expression of COL15A1 and TNC and maintenance of TGF-β1 induced histone H4 acetylation 
in cell progeny. 
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Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death in 
the world and as the ageing population grows, has been projected to increase to the third 
by 2030[1]. COPD is characterised by a persistent loss in lung function precipitating as 
shortness of breath in patients, with small airways disease and emphysema being the 
pathological manifestations of the disease. Small airways disease is the predominant 
site of obstruction in COPD[2] and describes changes in the airway walls of 4th – 16th 
generation bronchioles which are <2mm in diameter. These changes include heightened 
inflammation[3, 4] and increased ECM deposition in close proximity to the airway 
smooth muscle (ASM) layer[5] within the airway wall[6]. The overall effect of which 
being a thickened, more rigid, fibrotic airway wall wrapped around a lumen; 
subsequently decreasing lumen size and causing airway obstruction. Small airways 
disease has been shown to precede emphysematous changes[7], and thereby considered 
the primary pathological insult in COPD. Using primary mesenchymal cells, we have 
shown that cells from COPD smokers are hyperresponsive to cigarette smoke 
stimulation in vitro, depositing more ECM than those cells from non-COPD smokers[8, 
9].  
 
Although cigarette smoking is an established risk factor for COPD, not all smokers 
develop COPD.  The reasoning behind the same stimuli having variable outcomes on 
disease is the result of both genetic and epigenetic susceptibility. Epigenetic aberrancies 
in COPD have been described in epigenome-wide association studies (EWAS) 
describing differentially methylated CpG sites in leukocytes[10] and small airway 
epithelial cells[11], and we previously found that peripheral lung tissue and immune 
cells from COPD patients had greater levels of histone H4 acetylation at the CXCL8 
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promoter and decreased HDAC activity[12]. However, no studies to date have 
investigated if epigenetic dysregulation also occurs in genes involved in the 
pathogenesis of small airway fibrosis, namely ECM encoding genes. 
 
Epigenetics is a wide-encompassing term that is best described by Riggs[13] as 
mitotically or meiotically heritable changes to genetic function not attributable to gene 
sequence. The field encapsulates modifications made directly to DNA and post-
translational modification of histones. In this study, we will explore DNA methylation 
and histone acetylation, in the context of ECM gene expression, in ASM cells. We posit 
that epigenetic factors are critical in small airways disease in COPD. The aim of this 
study is to identify and investigate the underlying epigenetic mechanisms of an aberrant 
ECM gene response to TGF-β1 from primary human ASM cells from smokers with and 
without COPD. The study further delineates the role of epigenetic readers from the 
bromo- and extra-terminal domain (BET) protein family such as  Brd2 and Brd4, which 






Additional detail for all noted methods is provided in the online data supplement.  
 
Study subjects 
All human lung tissue obtained following written informed consent. Human ASM cells 
were obtained from bronchial airways of subjects with COPD or no obstructive lung 
disease. Patient demographics are provided in Supplement Table E1.  
 
Cell isolation & culture 
Airways were isolated from the lung and human ASM cells were isolated from the 
small airways (<2mm) of patients undergoing lung transplantation or lung resection for 
thoracic malignancies and cells were isolated as previously described[15]. These cells 
were used between passages 3-7. 
 
Focused microarray analysis 
cDNA from basal and TGF-β1 treated cells from n=7 non-COPD and n=7 COPD 
subjects was pooled and a focused microarray analysis was performed for each group 
using Taqman® Fast Array Plates targeting Human ECM Matrix & Adhesion 
Molecules (Life Technologies, Carlsbad, CA, USA) at baseline and upon stimulation.  
 
Quantitative PCR 
Quantitative PCR was performed as described previously[16]. Data from the reactions were 







Immunohistochemical analysis was performed as previously described[8]. Airway was 
assessed in formalin fixed paraffin embedded sections using hematoxylin & eosin, col 
15α1, and tenascin-C staining (n=4-5). Imaging was conducted using a Hamamatsu 
NanoZoomer (40X) and stain intensity quantified using Fiji Image J. 
 
Histone acetyltransferase and deacetylase activity 
Histone acetyltransferase results are expressed as amount of catalytic byproduct (CoA-
SH) per µg protein. Histone deacetylase activity results are expressed as amount of 
deacetylated substrate per µg protein. 
 
ChIP assay 
Chromatin Immunoprecipitation (ChIP) assay was carried out as previously 
described[17] using EZ-ChIP kit (Millipore, Bayswater, VIC, Australia) according to 
the manufacturer’s protocol. Data is presented as fold enrichment compared with the 
IgG negative control.  
 
Results 
COL15A1 and TNC are upregulated in COPD in vitro 
Initially we used a focused ECM microarray to analyse pooled cDNA (n=7 non-COPD; 
n=7 COPD) stimulated with TGF-1.  TGF-1 induced greater COL5A1, COL15A1, 
ITGA1, and TNC expression (relative to baseline) in ASM cells from COPD smokers 
compared to cells from non-COPD smokers (fig 1A). We next used real-time PCR to 
validate these findings. TGF-β1 induced heightened levels of COL15A1 expression 
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(fig. 1C) in COPD than in non-COPD smokers (63.2154.86±69.7415.19, n=7, range = 
115.7 versus 18.5113.98±4.54819.78, n=7, range = 34.68, p=0.0070155)).  Similarly, 
TGF-β1 induced TNC expression (fig. 1D) was also significantly (p=0.0041482, n=7) 
elevated in COPD  (9.49113.65±4.6983.651, n=7, range =26.96) compared to non-
COPD smokers (5.5085.499±1.6990.6006, n=7, range = 4.835).  However, there was 
no statistically significant difference between groups (n=7 per group) for COL5A1 (fig. 
1B) and ITGA1 (fig. 1E).  The data indicates a selective upregulation of COL15A1 and 
TNC expression in COPD by TGF-1 rather than a global TGF-1-induced 
upregulation of ECM genes. 
 
Collagen type XVα1 and tenascin C proteins deposed in ASM layer in small 
airways of COPD patients in vivo 
To validate our in vitro mRNA findings, we performed immunohistochemical staining 
of bronchioles from non-COPD and COPD smokers. Collagen type XVα1 (fig. 2A) and 
tenascin c (fig. 2B) – encoded for by genes COL15A1 and TNC, respectively – are found 
within the smooth muscle layer in vivo.  Of particular interest, is the specific and 
exclusive localization of collagen type XVα1 to the airway smooth muscle layer (figure 
2A). QQuantification of staining intensity found significantly showed trends towards 
higher levels of collagen type XVα1 (fig. 2C) and tenascin-C (fig. 2D) deposited in 
COPD airways in vivo, and a trend towards higher levels of TNC.  
 
Global HAT and HDAC activity unaltered in COPD ASM cells 
To investigate if activity of epigenetic enzymes differed with disease, we carried out 
HAT and HDAC activity assays. We found no significant (p=0.73024156) difference 
in HAT activity (fig. 3A) in the nuclear fraction of non-COPD (45.6441.92 ±21.0 4.92, 
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n=5, range=25.58) and COPD susceptible (50.1749.18 ± 38.358.81, n=4, range=41.73) 
smokers. Similarly, HDAC activity (fig. 3B) did not differ (p=0.42116857) between 
groups (non-COPD: 21.022.57 ± 5.2301.7, n=4, range=6.867. COPD: 25.123.56 ± 
4.516.64, n=4, range=21.29). 
 
HDAC inhibition alters TNC expression in COPD suggests acetylation plays a 
role in gene expression 
Although the overall HAT and HDAC activity did not differ between groups, we 
theorized that the differences may exist at a gene specific level. To investigate any 
acetylation differences at the COL15A1 and TNC promoter region, we treated cells with 
the pan-HAT inhibitor, curcumin (10µM) or the pan-HDAC inhibitor, TSA (100nM) 
prior to stimulation with TGF-β (10ng/ml) for 48 hours. HAT inhibition using curcumin 
resulted in no significant difference in TGF-β1-induced COL15A1 (fig. 4A) or TNC 
(fig. 4B) expression in cells from either patient group. In contrast, TGF-1-induced 
TNC expression differed significantly between cells from non-COPD (43.05±41.48, 
n=7, range=154.6) and COPD (156.9±189.3, n=7, range=246.5) susceptible smokers 
(p=0.0104) in the presence of TSA (fig 4D). To investigate the role of methylation at 
the COL15A1 and TNC promoter, cells were exposed to the DNMT1 inhibitor 5-
azacytidine (10µM) during cell division, resulting in significantly abrogated TGF-β1-
induced COL15A1 expression (fig. 4E) in ASM cells from non-COPD (18.79±53.61, 
p=0.0015, n=7, range=76.15) and COPD (23.11±74.52, p=0.0017, n=7, range=76.12) 
susceptible smokers, with no difference between groups. 
 
Histone 4 acetylated at COL15A1 and TNC promoter in COPD 
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We used ChIP-qPCR to investigate acetylation of histones H3 and H4 at the COL15A1 
and TNC promoter regions. Results show that histone H3 was not acetylated at the 
COL15A1 (fig. 5A) or TNC (fig. 5C) promoters at baseline or in response to stimulation 
with TGF-β1. In contrast, histone H4 acetylation was significantly upregulated at the 
COL15A1 (fig. 5B; ; n=4; p=0.0011<0.05) and TNC (fig. 5D; n=4; p=<0.050.0065) 
promoters in COPD cells in response to TGF-β1 stimulation (COL15A1 – non-COPD: 
22.95±25.02, range=26.99; COPD: 60.26±89.93, range=117.7. TNC – non-COPD: 
19.81±56.03, range=70.81; COPD: 159.0±177.1, range=195.9). 
 
Acetyl-histone recognition underpins COL15A1 and TNC expression in COPD 
To investigate the direct effect of the acetylated histone marks defined in figures 3B 
and 3D, cells were treated with the BET mimic JQ1(+) at a range of concentrations 
(1nM, 10nM, 100nM, and 1M). JQ1(+) at 1nM and 10nM had no effect on TGF-β1-
induced COL15A1 or TNC expression; whilst expression of both COL15A1 (fig. 6A; 
100nM p<0.05=0.0009, non-COPD: 1.401±2.83, range=3.03 COPD: 6.594±2.647, 
range=4.859; 1µM p<0.05=0.0003, non-COPD: 0.322±0.311, range=0.508 COPD: 
0.2198±0.176, range=0.317; n=65 non-COPD, n=55 COPD) and TNC (fig. 6B; 100nM 
p<0.05<0.0001, non-COPD: 0.533±0.707, range=1.559 COPD: 1.119±1.631, 
range=1.899; 1µM p<0.05<0.0001, non-COPD: 0.213±0.30, range=0.757 COPD: 
0.513±0.340, range=0.468; n=65 non-COPD, n=5 COPD) was significantly abrogated 
in cells from volunteers with COPD at 100nM and 1M JQ1(+). These data 
demonstrate a role for histone H4 acetylation in aberrant ECM gene expression in ASM 
cells from COPD patients. 
 
BET proteins maintain pathological Histone H4 Acetyl mark 
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To elucidate the extent which BET proteins play a role in histone H4 acetylation, we 
carried out ChIP-qPCR on hASM cells treated with JQ1(+) at the effective 
concentrations (100nM and 1µM) shown in figures 4A and 4C. The results show that 
Brd inhibition with 1µM JQ1(+) significantly ablated the detection of H4 acetylation at 
the COL15A1 ( 100nM p=0.0017; 1µM p=0.008<0.05; n=4 non-COPD, n=4 COPDper 
group; non-COPD: 9.07±11.64, range=12.53 COPD: 1.310±1.043, range: 1.293) and 
TNC (100nM p=0.0018; 1µM p=0.002<0.05; n=4 non-COPD, n=4 COPDper group; 





In this study we investigated the epigenetic modulation of ECM gene expression in 
human ASM cells.  We found that ASM cells expressed more COL15A1 and TNC 
mRNA in COPD upon stimulation with TGF-1 in vitro. The ECM proteins encoded 
by these genes, collagen XV1 and tenascin-C, were shown to be deposited within the 
ASM layer in human COPD airways in vivo, with collagen XV1 being 
significantlytrends towards higher deposition in COPD.  HDAC inhibition significantly 
attenuated TNC expression in COPD only, whilst DNMT1 inhibition with 5-azacytidine 
and HAT inhibition with Curcumin lead to no difference in response between COPD 
and non-COPD cells. We found increased H4 acetylation at the COL15A1 and TNC 
promoters in response to TGF-1 stimulation in COPD only. We competitively 
inhibited acetyl-lysine recognition by BET proteins with concentrations of JQ1(+) to 
show that COL15A1 and TNC mRNA expression depends on BET protein recognition 
of acetylated histones. Finally, we carried out ChIP-qPCR on cells pre-treated with 
 
 10 
JQ1(+). Interestingly, 1µM JQ1(+) pre-treatment lead to complete abrogation of TGF-
β1 induced histone H4 acetylation at the COL15A1 and TNC promoter region. Thereby 
demonstrating that BET proteins play a role in maintaining TGF-β1 induced histone 
H4 acetylation in COPD.  
 
To induce ECM expression, cells from each cohort were stimulated with TGF-1; a 
known pro-fibrotic cytokine shown to be elevated in COPD[18]. We used cells from 
non-COPD and COPD smokers to delineate epigenetic aberrations relative to COPD 
rather than smoking status. Further, we controlled for age and gender to limit 
confounding factors. We found that COPD hASM cells expressed significantly higher 
levels of COL15A1 and TNC mRNA in vitro and immunohistochemical staining 
demonstrated that these proteins are deposited within the ASM layer of small airways 
of COPD patients in vivo. This increased ECM is consistent with other studies of COPD 
smokers[8, 9, 19], and contributes to small airway fibrosis which has been shown to 
positively correlate with COPD severity[5].  
 
ECM proteins have inherent bioactive properties in addition to providing structural 
support. Tenascin-C is a glycoprotein which induces myofibroblast formation, cell 
migration and ameliorates production of other ECM proteins in vivo and in vitro[20-
22]. This emphasizes the critical role of tenascin-C in the onset and maintenance of 
fibrosis. Collagen XV1 is one of the lesser understood collagens but is expressed in 
basement membranes and in smooth and striated muscle of numerous organ 
systems[23]. Although increased levels of collagen XV1 have been noted in other 
fibrotic diseases[24], little is understood of its role in COPD. Its C-terminal fragment, 




HAT and HDAC activity were similar between non-COPD and COPD susceptible 
smokers. These findings agree with previous data regarding HAT activity but different 
to macrophages where decreased HDAC activity in COPD is reported [12]. This 
suggests that the epigenetic aberrations revealed by this study are a consequence of 
targeted gene- and cell-specific mechanisms rather than epigenome-wide changes. 
Cells were treated with epigenetic inhibitors curcumin, TSA, and 5-azacytidine to 
inhibit HATs, HDACs, and DNMT1, respectively. Our results shown no effect of HAT 
inhibition on COLXVA1 and TNC gene expression, whilst HDAC inhibition 
significantly attenuated TNC expression in ASM cells from COPD smokers, changes 
in COL15A1 were not statistically significant but they did follow a similar trend.   
 
DNMT1 inhibition with 5-azacytidine has been shown to inhibit the maintenance of 
cytosine methylation[26]. 5-azacytidine reduced COLXVA1 expression in both groups. 
It is well established that DNA methylation represses gene transcription[27]; given that 
our findings show that COLXVA1 expression is decreased upon DNMT1 inhibition, we 
surmise that our result is attributed to the increased expression of an upstream inhibitor 
of COLXVA1 rather than an indication that DNA methylation plays a role in the 
increased expression in COPD. However, this requires further experimentation to 
confirm this. In light of these findings, we determined that the likely mechanism 
underpinning increased COLXVA1 and TNC expression was local changes in histone 
acetylation status.  The use of non-selective inhibitors of these epigenetic enzymes 
should be confirmed in future studies using more selective agents or specific 
knockdown/over-expression of the target enzymes.  Coupling these data with RNA-
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sequencing will provide a greater overall view of the function of these epigenetic 
enzymes in the function of COPD ASM cells. 
 
ChIP-qPCR demonstrated that the promoter regions for COL15A1 and TNC were 
enriched for acetylated histone H4 in COPD. Histone acetylation leads to increased 
gene expression, with two mechanisms contributing to increased mRNA transcription. 
The first being that the addition of an acetyl moiety alters the charge of the histone, 
making it more negative and therein repelling the negatively charged DNA. This 
conformational change from tightly bound heterochromatin to loosely bound 
euchromatin allows transcriptional activators, co-factors, and enzymes such as RNA 
Polymerase II (RNAP2) access to the transcriptional start site. With Brd2 being shown 
to facilitate the recruitment of RNAP2[28]. Second, the acetylated lysine residue acts 
as a tag for a BET protein, such as Brd4. Brd4 then subsequently recruits transcriptional 
elongation factor b (P-TEFb), which relieves transcriptional pause of RNAP2 to  initiate 
mRNA transcription and elongation[29]. In light of our findings we posit that histone 
H4 acetylation is the mechanism underpinning increased expressed of COL15A1 and 
TNC in COPD ASM cells.  
 
To investigate whether acetylation played a direct role in the transcription of COL15A1 
and TNC mRNA, we used a small molecule competitive mimic or functional inhibitor 
of BET proteins’ acetyl-recognition site, JQ1(+). Pre-treatment of cells with 100nM 
and 1M of JQ1(+) significantly attenuated increased COL15A1 and TNC expression 
induced by TGF-1 in COPD, whilst the negative enantiomer JQ1(-) did not. Thereby 





BET proteins contain two tandem acetyl-binding domains, bromodomain 1 (BD1) and 
(BD2). BD1 and BD2 hold high sequence homology amongst the BET protein family, 
thereby resulting in a paucity of inhibitors specific to each Brd. Often, BET inhibitors 
act via dual binding of BD1 and BD2, but selective inhibitors of BD2, such as RVX-
208 have been developed[30]. The mechanism of action of JQ1(+) is well 
established[31] and it does not discriminate between BET proteins or BDs. The 
classical understanding of BET protein-mediated transcription involves their 
constitutive capacity as an epigenetic reader, however, Brd2 and Brd4 can also 
modulate acetylation and subsequent mRNA transcription in a specific and targeted 
manner. Brd4 knockout is embryonically lethal, however in vitro experiments have 
linked haploinsufficiency (Brd4-/+) of Brd4 to reduced levels of H3K14 and H4K12 
acetylation[32]. Brd2 and Brd4 preferentially binds to acetylated H3 and H4[29], with 
a higher affinity for the latter[33], and continues to remain bound to those acetylated 
histones associated with transcriptional start sites of genes essential for establishing 
basic cellular functions during mitosis[14, 29, 34]. It has been shown that at least half 
of the Brd4 “bookmarks” during mitosis are being carried over from interphase[35]. 
The capacity of BET proteins to remain associated with transcriptional start sites 
throughout the cell cycle is unlike most other bromodomain containing proteins and 
transcription factors that are evicted from the chromatin during M-phase[36, 37] along 
with the displacement of most acetyl marks[36, 38]. The subsequent transcription of 
these “marked” genes has been shown to commence early in G1[34] and indicate BET 
protein capacity to confer effective epigenetic memory of acetylated histones to 




With this in mind, we carried ChIP-qPCR against acetyl-H4 on hASM pre-treated with 
JQ1(+). JQ1(+) (100nM & 1M) significantly abrogated TGF-1-induced H4 
acetylation of the COL15A1 and TNC promoter region whilst the negative enantiomer, 
JQ1(-), did not exert such an effect. Thereby demonstrating that BET proteins play a 
role in maintaining an acetyl mark underpinning the overexpression of the 
aforementioned ECM genes. A study on Brd2 chromatin occupancy in a non-small lung 
cancer cell line H23[33] showed that JQ1(+) treatment depleted Brd2 chromatin 
association globally with no effect on global histone H4 acetylation. Interestingly, it 
was further shown that a small subpopulation of genomic regions that did not associate 
with Brd2 lost histone H4 acetylation in response to treatment with JQ1(+). The study 
did not investigate Brd4 occupation at regions of lost histone H4 acetylation in response 
to JQ1(+). Brd2 and Brd4 occupancy appears to be cell type specific as a separate study 
using murine Th17 cells found JQ1(+) treatment to displace global occupancy of Brd4, 
but not Brd2[28]. Our findings showing a loss of the acetyl mark post-JQ1(+) inhibition 
suggests that overexpression is likely linked to a BET protein, potentially Brd4, acting 
as a specific transcriptional modulator, rather than a classical epigenetic reader of 
acetylated lysine residues. Although its role as the latter would contribute to expression 
of the inherited mark during interphase[34]. Future studies should utilise experiments 
examining the effect of selective Brd2, Brd3, and Brd4 knockdown to confirm the exact 
function of these related proteins in the modulation of histone acetylation and 
subsequent ECM gene expression. These experiments may be combined with the use 
of the novel selective BRD4 specific inhibitors, ZL0420 and ZL0454[39]. We assert 
that our findings are bolstered by investigating genes directly, rather than overall global 
patterns, thereby allowing for detection of aberrancies that may otherwise be 
overlooked using bioinformatic methods such as peak calling and principal component 
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analysis. We concede that our findings are based on antibody-based methods which 
may lead to bias in acetylated histone H4 detection post-JQ1(+) treatment which may 
contribute to epitope occlusion resulting from changes to nearby PTMs. Future studies 
may wish to bolster their findings by correlating ChIP-based methods with tandem mass 
spectrometry (LC-MS/MS) to confirm a decrease in acetylated histones. Recent 
research shows that Brd4 possesses inherent histone acetyltransferase activity[40] and 
our findings may be explained by this phenomenon. Although we did not observe any 
differences in HAT activity in COPD ASM cells, future studies should examine the 
activity associated with immunoprecipitated Brd4 and other HAT enzymes to confirm 
this. In addition, ATAC-seq linked with ChIP-seq analysis of these cells may provide 
greater insight into the epigenetic control of COPD ASMs. 
 
Investigations into increased CXCL8 expression in asthmatic ASM showed increased 
histone H3 acetylation along with Brd3 and Brd4 binding at the CXCL8 promoter[41]; 
interestingly BET protein inhibition lead to significant abrogation of CXCL8 
expression. Studies using primary human ASM from asthmatic patients showed pre-
treatment with JQ1(+) prior to stimulation with TGF-β1 reduced Brd4 binding to the 
IL6 and CXCL8 promoters, which correlated with a decrease in IL6 and CXCL8 protein 
expression[42]. It has further been shown that the acetyl-lysine binding pocket of Brd2 
associates with Stat3 to recruit Th17 factors and enhance recruitment of RNAP2 to 
inflammatory genes, at which point co-bound Brd4 activates RNAP2 to commence 
transcriptional elongation[28]. Thereby demonstrating the capacity of Brd2 and Brd4 
to bind to the same gene with distinct roles in facilitating and sustaining gene 
expression. It is evident that BET proteins play an essential role in chromatin 
organisation, transcriptional elongation, and epigenetic memory yet there is a current 
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paucity of studies delineating the distinct roles of BET proteins in transcriptional 
activation during interphase and/or mitosis. We have shown, for the first time, that 
mesenchymal cells from COPD patients demonstrate an aberrant epigenetic response 
at the promoter region for ECM genes.  
 
Central to all epigenetic investigations is the conundrum of which came first: the 
epigenetic insult predisposing a patient to disease or an epigenetic aberration as a 
consequence of modifiable risk factors, such as smoking. By controlling for smoking, 
we have demonstrated that ASM cells from patients with COPD have an inherent 
epigenetic predisposition to histone acetylation underpinning increased ECM gene 
expression in small airways. We posit that increased COL15A1 and TNC expression is 
modulated by histone H4 acetylation; and that BET proteins act to maintain the 
acetylation mark in cell progeny. These novel findings shed light on a mechanism 
behind small airway fibrosis and highlight a new potential therapeutic avenue for the 
primary pathological insult in COPD.  
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